

MRI Studies of Addiction: Implications for Treatment Development

Marc N. Potenza, M.D., Ph.D.

***Associate Professor of Psychiatry
and Child Study***

***Director, Yale Gambling Center
of Research Excellence (CORE)***

***Director, Women and Addictions Core,
Women's Health Research at Yale***

Director of Neuroimaging, VA VISN1

MIRECC, VA CT Healthcare System

Yale University School of Medicine



Disclosures

- **Consultant to Boehringer Ingelheim**
- **Financial Interests in Somaxon**
- **Research Grants from Forest Laboratories, National Center for Responsible Gaming**
- **Research Gift from Mohegan Sun Casino**
- **Consultant to Law Firms and Federal Defenders Office on Issues Related to Impulse Control Disorders**



What is Addiction?

- **Addict (verb)** - “to devote or give (oneself) habitually or compulsively”; from Latin *addicere*
 - bound to or enslaved
- **Historical Shifts in Usage of Term**
- **Core Components of Addiction (Shaffer, 1999)**
 - Continued Behavior Despite Adverse Consequences
 - Diminished or Lost Control / Compulsive Engagement
 - Craving or Urge State Component




Changing Perspectives on Addiction

2001

Aided by brain imaging advances, scientists are looking for evidence that compulsive nondrug behaviors lead to long-term changes in reward circuitry

'Behavioral' Addictions: Do They Exist?




Verona Addiction Conference, June 8, 2010

2010

Shared brain vulnerabilities open the way for nonsubstance addictions: Carving addiction at a new joint?

Joseph Frascella,¹ Marc N. Potenza,² Lucy L. Brown,³ and Anna Rose Childress^{4,5}

Behavioral Addictions Debut in Proposed *DSM-V*



Holden, *Science*, 2001, 2010; Frascella et al, *Ann NY Acad Sci*, 2010

Relationship Between PG and SUDs

- **High Rates of Co-Occurrence**
 - Population and Clinical Samples
- **Similar Clinical Courses**
 - High Rates in Adolescence, Lower Rates in Older Adults
 - “Telescoping” Pattern in Women
- **Similar Clinical Characteristics**
 - Tolerance, Withdrawal, Repeated Attempts to Cut Back or Quit
 - Appetitive Urge or Craving States
- **Similar Biologies**
 - Genetic Contributions, Neural Circuits
- **Similar Treatments**
 - Self-Help, CBT, MI, Naltrexone and Nalmefene, N-AC



Impulsivity as an Endophenotype


- **Defining Impulsivity (Moeller et al, 2001)**
 - “A Predisposition Toward Rapid, Unplanned Reactions to Internal or External Stimuli [With Diminished] Regard to the Negative Consequences of These Reactions to the Impulsive Individual or to Others”
- **Impulsivity Across Psychiatric Groups**
 - ICDs, SUDs, Bipolar D/O, ADHD, ASPD, BPD, Suicidality, SIB
- **Behavioral Measures of Impulsivity**
 - Choice Impulsivity - Risk/Reward Assessment & Decision-Making Paradigms (Monetary Reward/Punishment, Discounting, Gambling Tasks)
 - Response Impulsivity - Disinhibition/Attentional Paradigms (Go/No-Go, Stroop)



Motivational Neural Systems and Addiction

- **Mesolimbic System**
 - **DA in Ventral Tegmental Area, Nucleus Accumbens**
- **Frontal Cortical Systems**
 - **5-HT, DA**
- **Important Roles for Other Neurotransmitter Systems**
 - **GABA, Glutamate, Opioids, ...**





Roles for Neurotransmitters

Neurotransmitter

Role in Impulse Control

Norepinephrine (NE) Arousal, Excitement

Serotonin (5HT) Behavior Initiation/Cessation

Dopamine (DA) Reward, Reinforcement

Opioids Pleasure, Urges




5-HT & Impulse Control


- **Low CSF 5-HIAA Associated w/ Impaired Impulse Control (Potenza and Hollander, 2002)**
- **Altered Biochemical and Behavioral Responses to m-CPP (5HT1R and 5HT2R Partial Agonist) (DeCaria et al, 1998)**
- **Blunted 5HT Response in vmPFC in Impulsive Aggression (Siever et al, 1999; New et al, 2002)**




vmPFC, PG and SUDs



Stroop
PG - Control
(Potenza et al,
2003, *Am J*
Psychiatry)




Gambling Tape
PG-Control
(Potenza et al, 2003,
Arch Gen Psychiatry)



Simulated Gambling
Reuter et al, 2005, *Nat Neurosci*

Controls > SUD/PG in vmPFC on IGT
Tanabe et al, 2007, *Hum Brain Mapp*

Paroxetine



Escitalopram, PG and Anxiety

QuickTime™ and a
TIFF (Uncompressed) decompressor
are needed to see this picture.



Impulsivity During Treatment

- Self-Reported Impulsivity Decreased During Treatment in a Placebo-Controlled Trial of Paroxetine in the Treatment of PG (Blanco et al., 2009)
- PG-YBOCS Scores and Measures of Impulsivity Were Correlated at Treatment Onset ($r=0.51$; $p=0.001$)
- Changes in Impulsivity Correlated with Changes in PG-YBOCS Scores ($r=0.49$; $p=0.002$)




Risk/Reward Decision-Making, Reward Processing & Addiction


- Subjects with PG or SUDs Perform Disadvantageously on Gambling Tasks (Petry et al, 2001; Bechara, 2003)
- Rapid Discounting of Rewards (Bickel et al, 1999; Petry et al, 2001)
- Behavioral Measures of Reward Discounting Associated with SUD Tx Outcome (Krishnan-Sarin et al, 2007)





Delay Discounting Impulsivity and Smoking Treatment Outcome



Small, Immediate Rewards Preferentially Activate Ventral Striatum and vmPFC



Reward Anticipation and Outcome Activate VS and vmPFC, Respectively




Reward Processing in Addiction


- **Adults w/ AD vs Those w/o AD Show Less Activation of NAc in Anticipation of Working for Monetary Reward (Hommer et al, 2004; Wrase et al, 2007)**
- **Similar Findings in Adolescents and Adults FH+ Vs. FH- for AD (Hommer et al, 2004)**
- **VS Activation in Adults w/AD Correlates Inversely with Self-Reported Impulsivity (Beck et al, 2009)**
- **Extends Across Addictions - Less Activation of NAc in PG vs. Control During Monetary Wins vs. Losses (Reuter et al, 2005)**



Less Ventral Striatal Activation in PG




**Addiction Tapes
(PG-C_{PG})+(CD-C_{CD})
Potenza, 2008**




**Reuter et al, Nature
Neurosci, 2005**


Ventral Striatal Dysfunction Implicated in DDS and ICDs in PD



DDS in PD
Evans et al, 2006




PG in PD, Steeves et al, 2009



**ICDs in PD, Rao et al,
in press**

PG Subjects Show Diminished WM Integrity (Lower FA) in Genu of CC




| | Mean(SD) FA Values | | F | p |
|--------|--------------------|------------|------|-------|
| | PG | HC | | |
| L Genu | 0.47(0.07) | 0.53(0.05) | 9.33 | 0.004 |
| R Genu | 0.47(0.07) | 0.53(0.06) | 8.17 | 0.007 |

Pharmacological Treatment of AD

- Shared Genetic Contributions to PG and EtOH Dependence (Slutske et al, 2000)
- FDA-Approved Drugs for AD (None for PG/ICDs)
 - Disulfiram, Naltrexone, Acamprosate
- Naltrexone and Other Opioid Antagonists Indirectly Modulate Dopamine Neurotransmission in VTA-NAc Pathway
- Might Naltrexone or Other (Mu-)Opioid Receptor Antagonists Be Effective in Treating PG?



Nalmefene: CGI



Predicting Outcome

- Among Subjects Receiving Active Drug (n=214) in Two Placebo-Controlled Trials of Naltrexone and Nalmefene, The Factor Most Strongly Associated with Outcome was a Family History of Alcoholism (OR=1.74; p=0.006)
- Among Subjects Receiving Higher Doses of Active Drug, Gambling Urges Were Associated with Treatment Outcome (OR=5.86; p<0.05)
- Among Those Receiving Placebo (n=70), Response Was Most Strongly Associated with Younger Age (OR=0.70; p=0.01)




Behavioral Therapies in Addiction

- Behavioral Therapies for Drug Addiction Are Efficacious and Widely Used (Carroll et al, 2008)
- Despite Their Widespread Use, Little is Known Regarding Brain Changes Associated with Treatment Outcomes in Behavioral Treatments for Addictions
- Specific Treatments May Demonstrate Efficacy Through Changes in Different Brain Circuits
- Specific Aspects of Outcome (Retention vs. Abstinence) May Differentially Relate to Specific Aspects of Brain Function




Reward Processing & Tx Outcome in CD




Zia et al, under review

Pre-Treatment fMRI Stroop Measures Associated with Tx Outcomes


fMRI Stroop Measures Change After Behavioral Tx (CBT and TAU)



z=50



z=6




z=-14

**Post-Tx Vs. Pre-Tx Contrast of
Incongruent Vs. Congruent
Stroop Stimuli**


n=12 subjects, $p < 0.005$; $k > 20$

DeVito et al, revise and resubmit

Poorer WM Integrity Associated with Shorter Duration of Cocaine Abstinence in CD Subjects



fMRI Stroop in Adolescent Smokers: Relationship with Tx Outcome, Attention




Conclusions & Future Directions

- **There Exist Multiple Shared Features Between PG and SUDs and These Have Implications for Treatment Development**
- **MRI Assessments Integrated into RCTs Investigating Therapies for Addiction Can Provide Important Information Relating to Neural Mechanisms of Action**
- **Specific Aspects of Outcome Appear Differentially Related to Brain Function**
- **Future Research Should Investigate Specific Therapies and Employ Information Gained to Develop Improved (Complementary) Treatments**



The International Society for Research on Impulsivity and Impulse Control Disorders (ISRI)



**www.impulsivity.org
(or contact marc.potenza@yale.edu)**

Acknowledgments



Women & Addictions

Carolyn Mazure

Rani Desai

Paul Maciejewski

Div Substance Abuse

Bruce Rounsaville

Kathleen Carroll

Suchitra Krishnan-Sarin

Stephanie O'Malley

Elaine Lavelle

Dana Cavallo

Ran Wu

Imaging

Todd Constable

Godfrey Pearlson

Rajita Sinha

Bruce Wexler

Robert Fulbright

Cheryl Lacadie

Patrick Worhunsky

Jiansong Xu

Judson Brewer

Hedy Kober

Elise DeVito

Michael Stevens

Linda Mayes

Genetics

Joel Gelernter

Seth Eisen

Hong Xian

Jeff Scherrer

Justine Giddens

RCTs

Jon Grant

SW Kim

Carlos Blanco

Eric Hollander

Gambling Center Of Excellence

Iris Balodis

Christine Franco

Sarah Yip

Justin Wareham

Scott Bullock

Jennifer Bellegarde

Monica Solorzano

Jessica Montoya

Katie VanBuskirk

Kourosh Zakeri

Translational

Jane Taylor

R. A. Chambers

CT Partnerships

Marvin Steinberg & CCPG

Loreen Rugle & PGS

NIH (NIDA, NIAAA, ORWH) VA (MIRECC, REAP) WHR DMHAS NCRG Moh Sun